Journal article · 2026 · Open access

Berberine-inspired evolution of mitochondria-targeting photocatalyst for two-photon-activatable tumor photoimmunotherapy

Shuyi Ning, Junjie Du, Dianyu Wang, Tingyu Jiang, Yang He, Xinchi Feng, Jianfeng Liu, Lijun Yang, Yulin Tian

Acta Pharmaceutica Sinica B · Published 1 October 2026 · DOI 10.1016/j.apsb.2026.09.028

Open full textCite this paper

In brief

“Berberine-inspired evolution of mitochondria-targeting photocatalyst for two-photon-activatable tumor photoimmunotherapy” is a 2026 journal article by Shuyi Ning and 8 co-authors, published in Acta Pharmaceutica Sinica B. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Acta Pharmaceutica Sinica B.

Citations
0
References
68
Authors
9

Abstract

Photoimmunotherapy, especially that mediated by photocatalytic therapy (PCT), has emerged as a highly promising antitumor modality for addressing the challenge of immunosuppressive tumor microenvironment. However, development of high-performance organic photoredox catalysts with long-wavelength excitation and organelle specificity for effective PCT remains challenging. Inspired by the natural photosensitizer berberine, we herein report a berberine-derived photocatalyst (BBR-2) for two-photon-activatable tumor photoimmunotherapy. Through a molecular engineering strategy, we rationally designed a specific donor– π –acceptor (D– π –A) molecular architecture that displays distinct aggregation-induced emission (AIE) properties and prominent two-photon absorption features, allowing for near-infrared (NIR) laser excitation. Upon light illumination, BBR-2 exhibits high type I/Ⅱ ROS generation capacity and pronounced photocatalytic activity to disturb the NADH/NAD + balance, surmounting the hypoxia limitation in cancer treatment. Moreover, BBR-2 causes mitochondrial dysfunction, promotes the release of mitochondrial DNA to stimulate the cyclic GMP–AMP synthase-stimulator of interferon genes (cGAS–STING) pathway, and induces necrosis-mediated immunogenic cell death (ICD). In breast tumor models, BBR-2-mediated photocatalysis achieves systemic immunoactivation to inhibit primary and distant tumors and prevent tumor lung metastasis. Overall, this work offers a reliable strategy for developing high-quality photocatalysts based on natural product modification for photoimmunotherapy, which has great potential for overcoming the restrictions of immunosuppressive microenvironment of hypoxic solid tumors.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ning, S., Du, J., Wang, D., Jiang, T., He, Y., Feng, X., Liu, J., Yang, L., & Tian, Y. (2026). Berberine-inspired evolution of mitochondria-targeting photocatalyst for two-photon-activatable tumor photoimmunotherapy. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.028

MLA 9

Ning, Shuyi, et al. “Berberine-inspired evolution of mitochondria-targeting photocatalyst for two-photon-activatable tumor photoimmunotherapy.” Acta Pharmaceutica Sinica B, 2026. https://doi.org/10.1016/j.apsb.2026.09.028.

Chicago

Ning, Shuyi, Junjie Du, Dianyu Wang, Tingyu Jiang, Yang He, Xinchi Feng, Jianfeng Liu, Lijun Yang, and Yulin Tian. 2026. “Berberine-inspired evolution of mitochondria-targeting photocatalyst for two-photon-activatable tumor photoimmunotherapy.” Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.028.

Harvard

Ning, S. et al. (2026) ‘Berberine-inspired evolution of mitochondria-targeting photocatalyst for two-photon-activatable tumor photoimmunotherapy’, Acta Pharmaceutica Sinica B. doi:10.1016/j.apsb.2026.09.028.

IEEE

S. Ning et al., “Berberine-inspired evolution of mitochondria-targeting photocatalyst for two-photon-activatable tumor photoimmunotherapy,” Acta Pharmaceutica Sinica B, 2026, doi: 10.1016/j.apsb.2026.09.028.

BibTeX

@article{ning2026berberine,
  title     = {{Berberine-inspired evolution of mitochondria-targeting photocatalyst for two-photon-activatable tumor photoimmunotherapy}},
  author    = {Ning, Shuyi and Du, Junjie and Wang, Dianyu and Jiang, Tingyu and He, Yang and Feng, Xinchi and Liu, Jianfeng and Yang, Lijun and Tian, Yulin},
  journal   = {Acta Pharmaceutica Sinica B},
  year      = {2026},
  doi       = {10.1016/j.apsb.2026.09.028},
  url       = {https://doi.org/10.1016/j.apsb.2026.09.028}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics

  • berberine
  • photoimmunotherapy
  • two-photon activation
  • mitochondrial targeting
  • aggregation-induced emission
  • two-photon absorption
  • near-infrared excitation
  • reactive oxygen species generation

Work with this paper

Most-cited papers in Engineering

All highly cited Engineering papers

Questions about this paper

How do I cite this paper in APA style?

Ning, S., Du, J., Wang, D., Jiang, T., He, Y., Feng, X., Liu, J., Yang, L., & Tian, Y. (2026). Berberine-inspired evolution of mitochondria-targeting photocatalyst for two-photon-activatable tumor photoimmunotherapy. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.028

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Acta Pharmaceutica Sinica B: sign in and open the full text from this page.

Who wrote this paper?

Shuyi Ning, Junjie Du, Dianyu Wang, Tingyu Jiang, Yang He, Xinchi Feng, Jianfeng Liu, Lijun Yang, Yulin Tian.

What is the DOI of this paper?

10.1016/j.apsb.2026.09.028, permanently at https://doi.org/10.1016/j.apsb.2026.09.028. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.